ENaC inhibitors and airway re-hydration in cystic fibrosis: State of the art

Current Molecular Pharmacology

Volumn 6, Issue 1, 2013, Pages 3-12

  Althaus, Mike ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Airway surface liquid; Amiloride; Cftr; Cystic fibrosis; Enac; Inhibitor; Sodium transport

Indexed keywords

AMILORIDE; AMILORIDE DERIVATIVE; AMINE; EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; GS 9411; PROTEINASE INHIBITOR; PURINERGIC RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; SODIUM;

AIRWAY; ARTICLE; CILIARY MOTILITY; CYSTIC FIBROSIS; HUMAN; ION TRANSPORT; LUNG FIBROSIS; MUCOCILIARY CLEARANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SODIUM ABSORPTION; SODIUM TRANSPORT; CHEMISTRY; DRUG EFFECT; METABOLISM; PATHOLOGY; REVIEW; DRUG EFFECTS;

AMILORIDE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL BLOCKERS; EPITHELIAL SODIUM CHANNELS; HUMANS; MUCOCILIARY CLEARANCE; PROTEASE INHIBITORS; PURINERGIC AGONISTS; SODIUM;

EID: 84884282606     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/18744672112059990025     Document Type: Article

References (97)

1. Rogers, C.S.; Stoltz, D.A.; Meyerholz, D.K.; Ostedgaard, L.S.; Rokhlina, T.; Taft, P.J.; Rogan, M.P.; Pezzulo, A.A.; Karp, P.H.; Itani, O.A.; Kabel, A.C.; Wohlford-Lenane, C.L.; Davis, G.J.; Hanfland, R.A.; Smith, T.L.; Samuel, M.; Wax, D.; Murphy, C.N.; Rieke, A.; Whitworth, K., Uc, A.; Starner, T.D.; Brogden, K.A.; Shilyansky, J.; McCray, P.B. Jr.; Zabner, J.; Prather, R.S.; Welsh, M.J. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science, 2008, 321, 1837-1841.
2. Kellerman, D.; Rossi Mospan, A.; Engels, J.; Schaberg, A.; Gorden, J.; Smiley, L. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm. Pharmacol. Ther., 2008, 21, 600-607.
3. Kunzelmann, K.; Schreiber, R. Airway epithelial cells- Hyperabsorption in CF? Int. J. Biochem. Cell Biol., 2012, 44(8):1232-1235.
4. Donaldson, S.H.; Bennett, W.D.; Zeman, K.L.; Knowles, M.R.; Tarran, R.; Boucher, R.C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med., 2006, 354, 241-250.
5. Goralski, J.L.; Boucher, R.C.; Button, B. Osmolytes and ion transport modulators: new strategies for airway surface rehydration. Curr. Opin. Pharmacol., 2010, 10, 294-299.
6. Hollenhorst, M.I.; Richter, K.; Fronius, M. Ion transport by pulmonary epithelia. J. Biomed. Biotechnol., 2011, 2011, 174306.
7. Pilewski, J.M.; Frizzell, R.A. Role of CFTR in airway disease. Physiol. Rev., 1999, 79, S215-S255.
8. Boucher, R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J., 2004, 23, 146-158.
9. Mall, M.; Hipper, A.; Greger, R.; Kunzelmann, K. Wild type but not deltaF508 CFTR inhibits Na+ conductance when coexpressed in Xenopus oocytes. FEBS Lett., 1996, 381, 47-52.
10. Stutts, M.J.; Canessa, C.M.; Olsen, J.C.; Hamrick, M.; Cohn, J.A.; Rossier, B.C.; Boucher, R.C. CFTR as a cAMP-dependent regulator of sodium channels. Science, 1995, 269, 847-850.
11. Greger, R.; Bleich, M.; Leipziger, J.; Ecke, D.; Mall, M.; Kunzelmann, K. Regulation of Ion Transport in Colonic Crypts. Physiology, 1997, 12, 62-66.
12. Shamsuddin, A.K.M.; Quinton, P.M. Surface Fluid Absorption and Secretion in Small Airways. J. Physiol., 2012, 590(Pt. 15), 3561-3574.
13. Wine, J.J. The genesis of cystic fibrosis lung disease. J. Clin. Invest., 1999, 103, 309-312.
14. Smith, J.J.; Travis, S.M.; Greenberg, E.P.; Welsh, M.J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell, 1996, 85, 229-236.
15. Zabner, J.; Smith, J.J.; Karp, P.H.; Widdicombe, J.H.; Welsh, M.J. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol. Cell, 1998, 2, 397-403.
16. Pezzulo, A.A.; Tang, X.X.; Hoegger, M.J.; Alaiwa, M.H.A.; Ramachandran, S.; Moninger, T.O.; Karp, P.H.; Wohlford-Lenane, C.L.; Haagsman, H.P.; van Eijk, M.: Bánfi, B.; Horswill, A.R.; Stoltz, D.A.; McCray, P.B. Jr.; Welsh, M.J.; Zabner, J. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature, 2012, 487, 109-113.
17. Matsui, H.; Grubb, B.R.; Tarran, R.; Randell, S.H.; Gatzy, J.T.; Davis, C.W.; Boucher, R.C. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell, 1998, 95, 1005-1015.
18. Knowles, M.R.; Boucher, R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest., 2002, 109, 571-577.
19. Mall, M.A. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J. Aerosol. Med. Pulm. Drug Deliv., 2008, 21, 13-24.
20. Tarran, R.; Grubb, B.R.; Gatzy, J.T.; Davis, C.W.; Boucher, R.C. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J. Gen. Physiol., 2001, 118, 223-236.
21. Tarran, R.; Button, B.; Boucher, R.C. Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu. Rev. Physiol., 2006, 68, 543-561.
22. Mall, M.; Grubb, B.R.; Harkema, J.R.; O'Neal, W.K.; Boucher, R.C. Increased airway epithelial Na+ absorption produces cystic fibrosis- like lung disease in mice. Nat. Med., 2004, 10, 487-493.
23. Mall, M.A. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Exp. Physiol., 2009, 94, 171-174.
24. Berdiev, B.K.; Qadri, Y.J.; Benos, D.J. Assessment of the CFTR and ENaC association. Mol. Biosyst., 2009, 5, 123-127.
25. Nagel, G.; Barbry, P.; Chabot, H.; Brochiero, E.; Hartung, K.; Grygorczyk, R. CFTR fails to inhibit the epithelial sodium channel ENaC expressed in Xenopus laevis oocytes. J. Physiol. (Lond.), 2005, 564, 671-682.
26. Rogers, C.S.; Abraham, W.M.; Brogden, K.A.; Engelhardt, J.F.; Fisher, J.T.; McCray, P.B.; McLennan, G.; Meyerholz, D.K.; Namati, E.; Ostedgaard, L.S.; Prather, R.S.; Sabater, J.R.; Stoltz, D.A.; Zabner, J.; Welsh, M.J. The porcine lung as a potential model for cystic fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 295, L240-L263.
27. Chen, J.-H.; Stoltz, D.A.; Karp, P.H.; Ernst, S.E.; Pezzulo, A.A.; Moninger, T.O.; Rector, M.V.; Reznikov, L.R.; Launspach, J.L.; Chaloner, K.; Zabner, J.; Welsh, M.J. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell, 2010, 143, 911-923.
28. Itani, O.A.; Chen, J.-H.; Karp, P.H.; Ernst, S.; Keshavjee, S.; Parekh, K.; Klesney-Tait, J.; Zabner, J.; Welsh, M.J. Human cystic fibrosis airway epithelia have reduced Cl- conductance but not increased Na+ conductance. Proc. Natl. Acad. Sci. USA, 2011, 108, 10260-10265.
29. Gentzsch, M.; Dang, H.; Dang, Y.; Garcia-Caballero, A.; Suchindran, H.; Boucher, R.C.; Stutts, M.J. The cystic fibrosis transmembrane conductance regulator impedes proteolytic stimulation of the epithelial Na+ channel. J. Biol. Chem., 2010, 285, 32227-32232.
30. Azad, A.K.; Rauh, R.; Vermeulen, F.; Jaspers, M.; Korbmacher, J.; Boissier, B.; Bassinet, L.; Fichou, Y.; Des Georges, M.; Stanke, F.; De Boeck, K.; Dupont, L.; Balascáková, M.; Hjelte, L.; Lebecque, P.; Radojkovic, D.; Castellani, C.; Schwartz, M.; Stuhrmann, M.; Schwarz, M.; Skalicka, V.; de Monestrol, I.; Girodon, E.; Férec, C.; Claustres, M.; Tümmler, B.; Cassiman, J.J.; Korbmacher, C.; Cuppens, H. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum. Mutat., 2009, 30, 1093-1103.
31. Rauh, R.; Diakov, A.; Tzschoppe, A.; Korbmacher, J.; Azad, A.K.; Cuppens, H.; Cassiman, J.-J.; Dötsch, J.; Sticht, H.; Korbmacher, C. A mutation of the epithelial sodium channel associated with atypical cystic fibrosis increases channel open probability and reduces Na+ self inhibition. J. Physiol. (Lond.), 2010, 588, 1211-1225.
32. Fronius, M.; Bogdan, R.; Althaus, M.; Morty, R.E.; Clauss, W.G. Epithelial Na+ channels derived from human lung are activated by shear force. Respir. Physiol. Neurobiol., 2010, 170, 113-119.
33. Bentley, P.J. Amiloride: a potent inhibitor of sodium transport across the toad bladder. J. Physiol. (Lond.), 1968, 195, 317-330.
34. Salako, L.A.; Smith, A.J. Effects of amiloride on active sodium transport by the isolated frog skin: evidence concerning site of action. Br. J. Pharmacol., 1970, 38, 702-718.
35. Lindemann, B.; van Driessche, W. Sodium-specific membrane channels of frog skin are pores: current fluctuations reveal high turnover. Science, 1977, 195, 292-294.
36. Diamond, J.M. Channels in epithelial cell membranes and junctions. Fed. Proc., 1978, 37, 2639-2643.
37. Canessa, C.M.; Horisberger, J.D.; Rossier, B.C. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature, 1993, 361, 467-470.
38. Canessa, C.M.; Schild, L.; Buell, G.; Thorens, B.; Gautschi, I.; Horisberger, J.D.; Rossier, B.C. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature, 1994, 367, 463-467.
39. App, E.M.; King, M.; Helfesrieder, R.; Köhler, D.; Matthys, H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am. Rev. Respir. Dis., 1990, 141, 605-612.
40. Knowles, M.R.; Church, N.L.; Waltner, W.E.; Yankaskas, J.R.; Gilligan, P.; King, M.; Edwards, L.J.; Helms, R.W.; Boucher, R.C. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med., 1990, 322, 1189-1194.
41. Köhler, D.; App, E.; Schmitz-Schumann, M.; Würtemberger, G.; Matthys, H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur. J. Respir. Dis. Suppl., 1986, 146, 319-326.
42. Riedler, J.; Huttegger, I. Pilotstudie zur Amiloridinhalation bei Kindern mit cystischer Fibrose. Klin. Padiatr., 1992, 204, 158-162.
43. Graham, A.; Hasani, A.; Alton, E.W.; Martin, G.P.; Marriott, C.; Hodson, M.E.; Clarke, S.W.; Geddes, D.M. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. J., 1993, 6, 1243-1248.
44. Cuthbert, A.W. New horizons in the treatment of cystic fibrosis. Br. J. Pharmacol 2011, 163, 173-183.
45. Hirsh, A.J.; Sabater, J.R.; Zamurs, A.; Smith, R.T.; Paradiso, A.M.; Hopkins, S.; Abraham, W.M.; Boucher, R.C. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J. Pharmacol. Exp. Ther., 2004, 311, 929-938.
46. Hofmann, T.; Stutts, M.J.; Ziersch, A.; Rückes, C.; Weber, W.M.; Knowles, M.R.; Lindemann, H.; Boucher, R.C. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am. J. Respir. Crit. Care Med., 1998, 157, 1844-1849.
47. Rodgers, H.C.; Knox, A.J. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur. Respir. J., 1999, 14, 693-696.
48. Hirsh, A.J.; Molino, B.F.; Zhang, J.; Astakhova, N.; Geiss, W.B.; Sargent, B.J.; Swenson, B.D.; Usyatinsky, A.; Wyle, M.J.; Boucher, R.C.; Smith, R.T.; Zamurs, A.; Johnson, M.R. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J. Med. Chem., 2006, 49, 4098-4115.
49. Hirsh, A.J.; Zhang, J.; Zamurs, A.; Fleegle, J.; Thelin, W.R.; Caldwell, R.A.; Sabater, J.R.; Abraham, W.M.; Donowitz, M.; Cha, B.; Johnson, K.B.; St George, J.A.; Johnson, M.R.; Boucher, R.C. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2- carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J. Pharmacol. Exp. Ther., 2008, 325, 77-88.
50. Zhou, Z.; Treis, D.; Schubert, S.C.; Harm, M.; Schatterny, J.; Hirtz, S.; Duerr, J.; Boucher, R.C.; Mall, M.A. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am. J. Respir. Crit. Care Med., 2008, 178, 1245-1256.
51. Hunt, T.; Atherton-Watson, H.C.; Axford, J.; Collingwood, S.P.; Coote, K.J.; Cox, B.; Czarnecki, S.; Danahay, H.; Devereux, N.; Howsham, C.; Hunt, P.; Paddock, V.; Paisley, D.; Young, A. Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines. Bioorg. Med. Chem. Lett., 2012, 22, 929-932.
52. Hunt, T.; Atherton-Watson, H.C.; Collingwood, S.P.; Coote, K.J.; Czarnecki, S.; Danahay, H.; Howsham, C.; Hunt, P.; Paisley, D.; Young, A. Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: Branched quaternary amines. Bioorg. Med. Chem. Lett., 2012, 22, 2877-2879.
53. A.J. Hirsh, George J.S.; Thelin, W.; Stapleton, K.; Montgomery, B.; Boucher, R.; Johnson, M.R. GS-9411: a potential aerosol pharmacotherapy for CF. Am. J. Respir. Crit. Care Med., 2009, 179, A1195.
54. Kleyman, T.R.; Carattino, M.D.; Hughey, R.P. ENaC at the cutting edge: regulation of epithelial sodium channels by proteases. J. Biol. Chem., 2009, 284, 20447-20451.
55. Vallet, V.; Chraibi, A.; Gaeggeler, H.P.; Horisberger, J.D.; Rossier, B.C. An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature, 1997, 389, 607-610.
56. Donaldson, S.H.; Hirsh, A.; Li, D.C.; Holloway, G.; Chao, J.; Boucher, R.C.; Gabriel, S.E. Regulation of the epithelial sodium channel by serine proteases in human airways. J. Biol. Chem., 2002, 277, 8338-8345.
57. Myerburg, M.M.; McKenna, E.E.; Luke, C.J.; Frizzell, R.A.; Kleyman, T.R.; Pilewski, J.M. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 294, L932-L941.
58. Nimishakavi, S.; Besprozvannaya, M.; Raymond, W.W.; Craik, C.S.; Gruenert, D.C.; Caughey, G.H. Activity and Inhibition of Prostasin and Matriptase on Apical and Basolateral Surfaces of Human Airway Epithelial Cells. Am. J. Physiol. Lung Cell Mol. Physiol., 2012, 303(2), L97-L106.
59. Tong, Z.; Illek, B.; Bhagwandin, V.J.; Verghese, G.M.; Caughey, G.H. Prostasin, a membrane-anchored serine peptidase, regulates sodium currents in JME/CF15 cells, a cystic fibrosis airway epithelial cell line. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287, L928-L935.
60. Verghese, G.M.; Tong, Z.Y.; Bhagwandin, V.; Caughey, G.H. Mouse prostasin gene structure, promoter analysis, and restricted expression in lung and kidney. Am. J. Respir. Cell Mol. Biol., 2004, 30, 519-529.
61. Caldwell, R.A.; Boucher, R.C.; Stutts, M.J. Neutrophil elastase activates near-silent epithelial Na+ channels and increases airway epithelial Na+ transport. Am. J. Physiol. Lung Cell Mol. Physiol., 2005, 288, L813-L819.
62. Prulière-Escabasse, V.; Clerici, C.; Vuagniaux, G.; Coste, A.; Escudier, E.; Planès, C. Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells. Respir. Res., 2010, 11, 141.
63. Garcia-Caballero, A.; Rasmussen, J.E.; Gaillard, E.; Watson, M.J.; Olsen, J.C.; Donaldson, S.H.; Stutts, M.J.; Tarran, R. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc. Natl. Acad. Sci. USA, 2009, 106, 11412-11417.
64. Cooley, J.; Sontag, M.K.; Accurso, F.J.; Remold-O'Donnell, E. SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition. Eur. Respir. J., 2011, 37, 1083-1090.
65. Zani, M.-L.; Tanga, A.; Saidi, A.; Serrano, H.; Dallet-Choisy, S.; Baranger, K.; Moreau, T. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Biochem. Soc. Trans., 2011, 39, 1441-1446.
66. Gaillard, E.A.; Kota, P.; Gentzsch, M.; Dokholyan, N.V.; Stutts, M.J.; Tarran, R. Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteases. Pflugers Arch., 2010, 460, 1-17.
67. Myerburg, M.M.; Butterworth, M.B.; McKenna, E.E.; Peters, K.W.; Frizzell, R.A.; Kleyman, T.R.; Pilewski, J.M. Airway surface liquid volume regulates ENaC by altering the serine proteaseprotease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis. J. Biol. Chem., 2006, 281, 27942-27949.
68. Tarran, R.; Trout, L.; Donaldson, S.H.; Boucher, R.C. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J. Gen. Physiol., 2006, 127, 591-604.
69. Coote, K.; Atherton-Watson, H.C.; Sugar, R.; Young, A.; MacKenzie-Beevor, A.; Gosling, M.; Bhalay, G.; Bloomfield, G.; Dunstan, A.; Bridges, R.J.; Sabater, J.R.; Abraham, W.M.; Tully, D.; Pacoma, R.; Schumacher, A.; Harris, J.; Danahay, H. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J. Pharmacol. Exp. Ther., 2009, 329, 764-774.
70. Tan, C.D.; Selvanathar, I.A.; Baines, D.L. Cleavage of endogenous ENaC and elevated abundance of ENaC are associated with increased Na(+) transport in response to apical fluid volume expansion in human H441 airway epithelial cells. Pflugers Arch., 2011, 462, 431-441.
71. Bridges, R.J.; Newton, B.B.; Pilewski, J.M.; Devor, D.C.; Poll, C.T.; Hall, R.L. Na+ transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am. J. Physiol. Lung Cell Mol. Physiol., 2001, 281, L16-L23.
72. Baranger, K.; Zani, M.-L.; Chandenier, J.; Dallet-Choisy, S.; Moreau, T. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J., 2008, 275, 2008-2020.
73. Sallenave, J.-M. Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity. Am. J. Respir. Cell Mol. Biol., 2010, 42, 635-643.
74. Gilligan, P.H. Microbiology of airway disease in patients with cystic fibrosis. Clin. Microbiol. Rev., 1991, 4, 35-51.
75. Stevens, T.; Ekholm, K.; Gränse, M.; Lindahl, M.; Kozma, V.; Jungar, C.; Ottosson, T.; Falk-Håkansson, H.; Churg, A.; Wright, J.L.; Lal, H.; Sanfridson, A. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J. Pharmacol. Exp. Ther., 2011, 339, 313-320.
76. Passero, C.J.; Carattino, M.D.; Kashlan, O.B.; Myerburg, M.M.; Hughey, R.P.; Kleyman, T.R. Defining an inhibitory domain in the gamma subunit of the epithelial sodium channel. Am. J. Physiol. Renal Physiol., 2010, 299, F854-F861.
77. Hobbs, C.A.; Blanchard, M.G.; Kellenberger, S.; Bencharit, S.; Cao, R.; Kesimer, M.; Walton, W.G.; Redinbo, M.R.; Stutts, M.J.; Tarran, R. Identification of SPLUNC1's ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airways. FASEB J., 2012, 26(10), 4348-4359.
78. Vallon, V.; Rieg, T. Regulation of renal NaCl and water transport by the ATP/UTP/P2Y2 receptor system. Am. J. Physiol. Renal Physiol., 2011, 301, F463-F475.
79. Devor, D.C.; Pilewski, J.M. UTP inhibits Na+ absorption in wildtype and DeltaF508 CFTR-expressing human bronchial epithelia. Am. J. Physiol., 1999, 276, C827-C837.
80. Kunzelmann, K.; Bachhuber, T.; Regeer, R.; Markovich, D.; Sun, J.; Schreiber, R. Purinergic inhibition of the epithelial Na+ transport via hydrolysis of PIP2. FASEB J., 2005, 19, 142-143.
81. Mace, O.J.; Woollhead, A.M.; Baines, D.L. AICAR activates AMPK and alters PIP2 association with the epithelial sodium channel ENaC to inhibit Na+ transport in H441 lung epithelial cells. J. Physiol. (Lond.), 2008, 586, 4541-4557.
82. Mall, M.; Wissner, A.; Gonska, T.; Calenborn, D.; Kuehr, J.; Brandis, M.; Kunzelmann, K. Inhibition of amiloride-sensitive epithelial Na(+) absorption by extracellular nucleotides in human normal and cystic fibrosis airways. Am. J. Respir. Cell Mol. Biol., 2000, 23, 755-761.
83. Poulsen, A.N.; Klausen, T.L.; Pedersen, P.S.; Willumsen, N.J.; Frederiksen, O. Regulation of ion transport via apical purinergic receptors in intact rabbit airway epithelium. Pflugers Arch., 2005, 450, 227-235.
84. Mall, M.; Gonska, T.; Thomas, J.; Schreiber, R.; Seydewitz, H.H.; Kuehr, J.; Brandis, M.; Kunzelmann, K. Modulation of Ca2+- activated Cl- secretion by basolateral K+ channels in human normal and cystic fibrosis airway epithelia. Pediatr. Res., 2003, 53, 608-618.
85. Olivier, K.N.; Bennett, W.D.; Hohneker, K.W.; Zeman, K.L.; Edwards, L.J.; Boucher, R.C.; Knowles, M.R. Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. Am. J. Respir. Crit. Care Med., 1996, 154, 217-223.
86. Basoglu, O.K.; Pelleg, A.; Essilfie-Quaye, S.; Brindicci, C.; Barnes, P.J.; Kharitonov, S.A. Effects of aerosolized adenosine 5'- triphosphate vs adenosine 5'-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest, 2005, 128, 1905-1909.
87. Cushley, M.J.; Tattersfield, A.E.; Holgate, S.T. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br. J. Clin. Pharmacol., 1983, 15, 161-165.
88. Gaba, S.J.; Bourgouin-Karaouni, D.; Dujols, P.; Michel, F.B.; Prefaut, C. Effects of adenosine triphosphate on pulmonary circulation in chronic obstructive pulmonary disease. ATP: a pulmonary vasoregulator? Am. Rev. Respir. Dis., 1986, 134, 1140-1144.
89. Bennett, W.D.; Olivier, K.N.; Zeman, K.L.; Hohneker, K.W.; Boucher, R.C.; Knowles, M.R. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am. J. Respir. Crit. Care Med., 1996, 153, 1796-1801.
90. Pendergast, W.; Yerxa, B.R.; Douglass, J.G.; Shaver, S.R.; Dougherty, R.W.; Redick, C.C.; Sims, I.F.; Rideout, J.L. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'- polyphosphates. Bioorg. Med. Chem. Lett., 2001, 11, 157-160.
91. Sabater, J.R.; Mao, Y.M.; Shaffer, C.; James, M.K.; O'Riordan, T.G.; Abraham, W.M. Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep. J. Appl. Physiol., 1999, 87, 2191-2196.
92. Noone, P.G.; Hamblett, N.; Accurso, F.; Aitken, M.L.; Boyle, M.; Dovey, M.; Gibson, R.; Johnson, C.; Kellerman, D.; Konstan, M.W.; Milgram, L.; Mundahl, J.; Retsch-Bogort, G.; Rodman, D.; Williams-Warren, J.; Wilmott, R.W.; Zeitlin, P.; Ramsey, B.; Cystic Fibrosis Therapeutics Development Research Group. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr. Pulmonol., 2001, 32, 122-128.
93. Yerxa, B.R.; Sabater, J.R.; Davis, C.W.; Stutts, M.J.; Lang-Furr, M.; Picher, M.; Jones, A.C.; Cowlen, M.; Dougherty, R.; Boyer, J.; Abraham, W.M.; Boucher, R.C. Pharmacology of INS37217 [P(1)- (uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther., 2002, 302, 871-880.
94. Deterding, R.R.; Lavange, L.M.; Engels, J.M.; Mathews, D.W.; Coquillette, S.J.; Brody, A.S.; Millard, S.P.; Ramsey, B.W. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am. J. Respir. Crit. Care Med., 2007, 176, 362-369.
95. Deterding, R.; Retsch-Bogart, G.; Milgram, L.; Gibson, R.; Daines, C.; Zeitlin, P.L.; Milla, C.; Marshall, B.; Lavange, L.; Engels, J.; Mathews, D.; Gorden, J.; Schaberg, A.; Williams, J.; Ramsey, B.; Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr. Pulmonol., 2005, 39, 339-348.
96. Accurso, F.J.; Moss, R.B.; Wilmott, R.W.; Anbar, R.D.; Schaberg, A.E.; Durham, T.A.; Ramsey, B.W. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med., 2011, 183, 627-634.
97. Stick, S.M.; Sly, P.D. Exciting new clinical trials in cystic fibrosis: infants need not apply. Am. J. Respir. Crit. Care Med., 2011, 183, 1577-1578.